These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7253510)

  • 21. [Cosaldon retard in the treatment of certain maculopathies (author's transl)].
    Starzycka M; Krukar-Bastrowa K
    Klin Oczna; 1980 Jun; 82(6):315-6. PubMed ID: 7406972
    [No Abstract]   [Full Text] [Related]  

  • 22. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential role for Ginkgo biloba extract in the treatment of glaucoma.
    Ritch R
    Med Hypotheses; 2000 Feb; 54(2):221-35. PubMed ID: 10790757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of intravitreal triamcinolone on intraocular pressure.
    Kramar M; Vu L; Whitson JT; He YG
    Curr Med Res Opin; 2007 Jun; 23(6):1253-8. PubMed ID: 17559723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The clinical efficacy of tanakan in patients with stage-I atherosclerotic circulatory encephalopathy].
    Rudenko AE; Lushchik UB; Dzhumik VA
    Lik Sprava; 1997; (2):99-101. PubMed ID: 9333499
    [No Abstract]   [Full Text] [Related]  

  • 26. Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre.
    Tatlipinar S; Dinç UA; Yenerel NM; Görgün E
    Clin Exp Optom; 2012 Jan; 95(1):94-8. PubMed ID: 21954975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Delayed-action pervincamine forte in circulatory disorders of the posterior segment of the eye].
    Bregeat P; Ryzman P
    Rev Otoneuroophtalmol; 1975; 47(5):353-8. PubMed ID: 1215739
    [No Abstract]   [Full Text] [Related]  

  • 28. [Long-term therapy of vascular permeability disorders using anthocyanosides].
    Neumann L
    Munch Med Wochenschr; 1973 May; 115(20):952-4. PubMed ID: 4740456
    [No Abstract]   [Full Text] [Related]  

  • 29. [Intravitreal application of triamcinolone--our experiences].
    Konjević Pernar S; Vatavuk Z; Bencić G; Pentz A; Mandić Z
    Acta Med Croatica; 2006; 60(2):133-5. PubMed ID: 16848205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Contribution of pyridinol-carbamate in ophthalmologic therapeutics].
    Pouliquen Y; Guyot-Argenton C
    Nouv Presse Med; 1972 Jan; 1(3):199-200. PubMed ID: 5061538
    [No Abstract]   [Full Text] [Related]  

  • 31. [Long-term therapy of retinal vasculopathies with oral administration of high doses of O-(beta-hydroxyethyl)-rutoside].
    Agolini G; Cavallini GM
    Clin Ter; 1987 Jan; 120(2):101-10. PubMed ID: 2972438
    [No Abstract]   [Full Text] [Related]  

  • 32. [Experience with Cosaldon in the treatment of circulatory disorders in the ophthalmological practice].
    Stark H
    Klin Monbl Augenheilkd; 1969 Jul; 155(1):104-9. PubMed ID: 5355393
    [No Abstract]   [Full Text] [Related]  

  • 33. [Value of non-IOP lowering therapy for glaucoma].
    Cybulska-Heinrich A; Mozaffarieh M; Flammer J
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):114-9. PubMed ID: 23430676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ginkgo biloba extract increases ocular blood flow velocity.
    Chung HS; Harris A; Kristinsson JK; Ciulla TA; Kagemann C; Ritch R
    J Ocul Pharmacol Ther; 1999 Jun; 15(3):233-40. PubMed ID: 10385132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events after intravitreal infliximab (Remicade).
    Giganti M; Beer PM; Lemanski N; Hartman C; Schartman J; Falk N
    Retina; 2010 Jan; 30(1):71-80. PubMed ID: 19996827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experience with retinal phosphatides in the therapy of glaucomatous visual field changes (author's transl)].
    Weiss H; Klemen U; Kosmath B
    Klin Monbl Augenheilkd; 1973 Dec; 163(6):704-10. PubMed ID: 4788869
    [No Abstract]   [Full Text] [Related]  

  • 37. [Experiences with drug therapy in association with ischaemic vascular disease of the fundus oculi (author's transl)].
    Gafner F
    Klin Monbl Augenheilkd; 1977 May; 170(5):741-4. PubMed ID: 894971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current drug patenting for retinal diseases: beyond VEGF inhibitors.
    Mucke HA; Mucke PM
    IDrugs; 2010 Jan; 13(1):30-7. PubMed ID: 20024845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [On the treatment of arteriosclerotic retinopathy with Cosaldon A+E (author's transl)].
    Zielinski HW
    Klin Monbl Augenheilkd; 1978 Dec; 173(6):857-64. PubMed ID: 732204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data on the treatment of arteriosclerotic and diabetic retinopathy.
    Pék L; Szentirmay K
    Ther Hung; 1974; 22(1):40-3. PubMed ID: 4844932
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.